Management of the patient and family with neurofibromatosis 2: a consensus conference statement

References

• Trofatter JA, MacCollin MM, Rutter JL, et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 1993;72:791–800.
   PubMed Web of Science ®Google Scholar
• Rouleau GA, Merel P, Lutchman M, et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 1993;363:515–21.
   PubMed Web of Science ®Google Scholar
• Evans DGR, Huson SM, Donnai D, et al. A clinical study of type 2 neurofibromatosis. Q 3 Med 1992;84:603–18.
   PubMedGoogle Scholar
• Parry DM, Eldridge R, Kaiser-Kupfer MI, Bouzas EA, Pikus A, Patronas N. Neurofibromatosis 2 (NF2): clinical character-istics of 63 affected individuals and clinical evidence for heterogeneity. Am 3 Med Genet 1994;52: 450–61.
   Google Scholar
• Mautner VF, Lindenau M, Baser ME, et al. The neuroimaging and clinical spectrum of neurofibromatosis 2. Neurosurgery 1996;38:880–5.
   PubMed Web of Science ®Google Scholar
• Mautner VF, Tatagiba M, Lindenau M, et al. Spinal tumors in patients with neurofibromatosis type 2: MR imaging study of frequency, multiplicity, and variety [published erratum appears in Am 3 Res Am I Roentgenol 1996;166:1231]. Am 3 Res Am Roentgenol 1995;165:951–5.
   PubMed Web of Science ®Google Scholar
• Evans DGR, Huson SM, Donnai D, et al. A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Preva-lence, mutation rate, fitness, and confirmation of maternal transmission effect on severity. 3 Med Genet 1992;29: 841–6.
   Google Scholar
• Mautner VF, Tatagiba M, Guthoff R, Samii M, Pulst SM. Neurofibromatosis in the pediatric age group. Neurosurgery 1993;33:92–6.
   Google Scholar
• MacCollin M, Mautner VF. The diagnosis and management of neurofibromatosis 2 in childhood. Sem Pediatr Neurol 1998;5:243–52.
   PubMedGoogle Scholar
• Evans DGR, Birch JM, Ramsden RT. Paediatric presentation of type 2 neurofibromatosis. Arch Dis Childh 1999;81: 496–9.
   Google Scholar
• Nunes F, MacCollin M. Neurofibromatosis 2 in the pediatric population. 3 Child Neurol 2003;18:718–24.
   PubMedGoogle Scholar
• National Institutes of Health Consensus Development Con-ference. Neurofibromatosis Conference Statement. Arch Neurol 1988;45:575–8.
   PubMedGoogle Scholar
• Consensus Development Panel. National Institutes of Health Consensus Development Conference Statement on Acoustic Neuroma, December 11-13, 1991. Arch N eurol1994; 51:201–7.
   PubMedGoogle Scholar
• Baser ME, Friedman JM, Wallace AJ, Ramsden RT, Joe H, Evans DGR. Evaluation of clinical diagnostic criteria for neurofibromatosis 2. Neurology 2002;59:1759–65.
   PubMed Web of Science ®Google Scholar
• Evans DG, Lye R, Neary W, et al. Probability of bilateral disease in people presenting with a unilateral vestibular schwannoma. I Neurol Neurosurg Psychiatry 1999;66:764–7.
   Google Scholar
• Wu CL, Neary W, Thakker N, et al. Differential diagnosis of type 2 neurofibromatosis: molecular discrimination of NF2 and sporadic vestibular schwannomas. 3 Med Genet 1998;35:973–7.
   Google Scholar
• Mohyuddin A, Neary W, Wallace A, et al. Molecular genetic analysis of the NF2 gene in young patients with unilateral vestibular schwannomas. 3 Med Genet 2002;39:311–15.
   Google Scholar
• Baser ME, Makariou EV, Parry DM. Predictors of vestibular schwannoma growth in patients with neurofibromatosis type 2. Neurosurg 2002;96: 217–22.
   Google Scholar
• Maumer VF, Baser ME, Thakker SD, Feiger UM, Friedman JM, Kluwe L. Vestibular schwannoma growth in patients with neurofibromatosis type 2: a longitudinal study. 3 Neurosurgery 2002;96:223–8.
   Google Scholar
• Baser ME, Friedman JM, Aeschliman D, et al. Predictors of the risk of mortality in neurofibromatosis 2. Am 3 Hum Genet 2002;71:715–23.
   PubMed Web of Science ®Google Scholar
• Otsuka 0, Saito K, Nagatani T, Yoshida J. Age at symptom onset and long-term survival in patients with neurofibromatosis Type 2.3 Neurosurg 2003;99: 480–3,
   Google Scholar
• Onishi A, Nada 0. Ultrastructure of the onion bulb-like lamellated structure observed in the sural nerve in a case of von Recklinghausen's disease. Acta Neuropathol (Berl) 1972;20: 258–63.
   Google Scholar
• Trivedi R, Byrne J, Huson SM, Donaghy M. Focal amyo-trophy in neurofibromatosis 2. I Neurol Neurosurg Psychiat 2000;69:257–61.
   Google Scholar
• Gijtenbeek JMM, Gabreels-Festen AAWM, Lammens M, Zwarts MJ, van Engelen BGM. Mononeuropathy multiplex as the initial manifestation of neurofibromatosis type 2. Neurology 2001;56:1776–8.
   Google Scholar
• Sperfeld AD, Hein C, Schroder JM, Ludolph AC, Hanemann CO. Occurrence and characterisation of peripheral nerve involvement in neurofibromatosis type 2. Brain 2002;125: 996–1004.
   Google Scholar
• Hagel C, Lindenau M, Lamszus K, Kluwe L, Stavrou D, Mautner VF. Polyneuropathy in neurofibromatosis 2: clinical findings, molecular genetics and neuropathological alterations in sural nerve biopsy specimens. Acta Neuropathol (Berl) 2002;104:179–87.
   PubMed Web of Science ®Google Scholar
• Ragge NK, Baser ME, Klein J, et al. Ocular abnormalities in neurofibromatosis 2. Am 3 Ophthalmol 1995;120:634–41.
   PubMed Web of Science ®Google Scholar
• Mautner VF, Lindenau M, Baser ME, Kluwe L, Gottschalk J. Skin abnormalities in neurofibromatosis 2. Arch Dermatol 1997;133: 1539–43.
   Google Scholar
• Patronas NJ, Courcoutsakis N, Bromley CM, Katzman GL, MacCollin M, Parry DM. Intramedullary and spinal canal tumours in patients with neurofibromatosis 2: MR imaging findings and correlation with genotype. Radiology 2001;218:434–42.
   PubMedGoogle Scholar
• Sobel RA, Wang Y. Vestibular (acoustic) schwannomas: histological features in neurofibromatosis 2 and in unilateral cases. 3 Neuropathol Exp Neurol 1993;52: 106–13.
   Google Scholar
• Baser ME, Evans DGR, Jackler RK, Sujansky E, Rubenstein A. Malignant peripheral nerve sheath tumours, radiotherapy, and neurofibromatosis 2. Br 3 Cancer 2000;82: 998.
   Google Scholar
• McGaughran JM, Harris DI, Donnai D, et al. A clinical study of type 1 neurofibromatosis in north west England.j Med Genet 1999;36:197–203.
   PubMed Web of Science ®Google Scholar
• Evans DG, Baser ME, McGaughran J, Sharif S, Howard E, Moran A. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. 3 Med Genet 2002;39:311–14.
   PubMed Web of Science ®Google Scholar
• Halliday AL, Sobel RA, Martuza RL. Benign spinal nerve sheath tumours. Their occurrence sporadically and in neuro-fibromatosis types 1 and 2. l Neurosurg 1991;74: 248–53.
   Google Scholar
• Morrison H, Sherman LS, Legg J, et al. The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev 2001;15:968–80.
   PubMed Web of Science ®Google Scholar
• Rong R, Surace El, Haipek CA, Gutmann DH, Ye K. Serine 518 phosphorylation modulates merlin intramolecular associa-tion and binding to critical effectors important for NF2 growth suppression. Oncogene 2004 Sep 20 [Epub ahead of print].
   Google Scholar
• Mérel P, Hoang-Xuan K, Sanson M, et al. Screening for germ-line mutations in the NF2 gene. Genes Chromosomes Cancer 1995;12:117–27.
   PubMedGoogle Scholar
• Parry DM, MacCollin MM, Kaiser-Kupfer MI, et al. Germ-line mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities. Am 3 Hum Genet 1996;59: 529–39.
   Google Scholar
• Ruttledge MH, Andermann AA, Phelan CM, et al. Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease. Am l Hum Genet 1996;59:331–42.
   PubMed Web of Science ®Google Scholar
• Evans DGR, Trueman L, Wallace A, Collins S, Strachan T. Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations. I Med Genet 1998;35: 450–5.
   Google Scholar
• Kluwe L, MacCollin M, Tatagiba M, et al. Phenotypic variability associated with 14 splice-site mutations in the NF2 gene. Am Med Genet 1998;77:228–33.
   Google Scholar
• Baser ME, Kurarnoto L, Joe H, et al. Genotype-phenotype correlations for nervous system tumors in neurofibromatosis 2: a population-based study. Am l Hum Genet 2004;75(2). [Epub ahead of print].
   Google Scholar
• Evans DGR, Wallace AJ, Wu CL, Trueman L, Ramsden RT, Strachan T. Somatic mosaicism: a common cause of classic disease in tumour-prone syndromes? Lessons from type 2 neurofibromatosis. Am 3 Hum Genet 1998;63: 727–36.
   Google Scholar
• Kluwe L, Mautner V-F. Mosaicism in sporadic neurofibro-matosis-2 patients. Hum Mol Genet 1998;7: 2051–5.
   Google Scholar
• Moyhuddin A, Baser ME, Watson C, et al. Somatic mosaicism in neurofibromatosis 2: prevalence and risk of disease transmission to offspring. l Med Genet 2003;40:459–63.
   PubMed Web of Science ®Google Scholar
• Kluwe L, Mautner VF, Heinrich B, et al. Molecular study of frequency of mosaicism in neurofibromatosis 2 patients with bilateral vestibular schwannomas. l Med Genet 2003;40:109–14.
   PubMed Web of Science ®Google Scholar
• Jacoby L, Jones D, Davis K, et al. Molecular analysis of the NF2 tumor suppressor in schwannomatosis. Am l Hum Genet 1997;61:1293–302.
   PubMedGoogle Scholar
• Evans DG, Watson C, King A, Wallace A, Baser M. Multiple meningiomas: differential involvement of NF2 in children and adults. l Med Genet 2005;42: 45–8.
   Google Scholar
• Charabi S, Tos M, Thomsen J, Borgesen SE. Suboccipital acoustic neuroma surgery: Results of decentralized neuro-surgical tumour removal in Denmark. Acta Otolaryngol 1992;112:810–15.
   PubMed Web of Science ®Google Scholar
• Buchman CA, Chen DA, Flannagan P, Wilberger JE, Maroon JC. The learning curve for acoustic tumor surgery. Laryngo-scope 1996;106:1406–11.
   PubMed Web of Science ®Google Scholar
• McCarthy BJ, Davis FG, Freels S, et al. Factors associated with survival in patients with meningioma. 3 Neurosurg 1998;88:831–9.
   PubMed Web of Science ®Google Scholar
• Jackler RK. The perils of decentralized care in otology/ neurotology. Am l Otol 1998;19:691–2.
   Google Scholar
• Welling DB, Slater PW, Thomas RD, McGregor JM, Good-man JE. The learning curve in vestibular schwannoma surgery. Am3 Otol 1999;20: 644–8.
   Google Scholar
• Evans DGR, Newton V, Neary W, et al. Use of MRI and audiological tests in pre-symptomatic diagnosis of type 2 neurofibromatosis (NF2). I Med Genet 2000;37:944–7.
   Google Scholar
• MacCollin M, Mohney T, Trofatter J, Wertelecki W, Ramesh V, Gusella J. DNA diagnosis of neurofibromatosis 2. Altered coding sequence of the merlin tumour suppressor in an extended pedigree. l Am Med Assoc 1993;270:2316–20.
   Google Scholar
• Kluwe L, Freidrich RE, Tatagiba M, Mautner V. Presympto-matic diagnosis for children of sporadic neurofibromatosis 2 patients: a method based on tumor analysis. Genet Med 2002;4:27–30.
   Google Scholar
• Ruttledge MH, Narod SA, Dumanski JP, et al. Presympto-matic diagnosis for neurofibromatosis 2 with chromosome 22 markers. Neurology 1993;43:1753–60.
   Google Scholar
• Sainio M, Strachan T, Blomstedt G, et al. Presymptomatic DNA and MRI diagnosis of neurofibromatosis 2 with mild clinical course in an extended pedigree. Neurology 1995;45:1314–22.
   Google Scholar
• Baser ME, Mautner V-F, Ragge NK, et al. Presymptomatic diagnosis of neurofibromatosis 2 using linked genetic markers, neuroimaging, and ocular examinations. Neurology 1996;47: 1269–77.
   Google Scholar
• Rowe JG, Radatz M, Walton L, Kemeny AA. Stereotactic radiosurgery for type 2 neurofibromatosis acoustic neuromas: patient selection and tumour size. Stereotact Funct Neurosurg 2002;79:107–16.
   PubMed Web of Science ®Google Scholar
• Rowe JG, Radatz MW, Walton L, Soanes T, Rodgers J, Kemeny AA. Clinical experience with gamma knife stereotactic radiosurgery in the management of vestibular schwannomas secondary to type 2 neurofibromatosis. 3 Neurol Neurosurg Psychiatry 2003;74:1288–93.
   PubMed Web of Science ®Google Scholar
• Shin M, Ueki K, Kurita H, Kirino T. Malignant transforma-tion of a vestibular schwannoma after gamma knife radiosurgery. Lancet 2002;360:309–10.
   PubMed Web of Science ®Google Scholar
• Friedmann RA, Slattery WH, Brackmann DE, Shwartz MS, Hitselberger WE. Resection of acoustic neuroma following failed stereotactic radiosurgical treatment: facial nerve outcome, Baguley DM, Ramsden RT, Moffat DA (eds). Fourth International Conference on Vestibular Schwannoma and Other CPA Lesions. Conference Proceedings, pp. 29–30. Bungay: Im-mediate Proceedings.
   Google Scholar